Generic Price-Fixing Lawsuit Grows As More Companies, Two Executives Named Defendants
Executive Summary
US state attorneys general name executives from Mylan and Emcure as defendants, and list may further expand as investigation continues into additional companies and drugs.
You may also be interested in...
Two India Firms In Fresh FDA Trouble: Emcure Hit By Warning Letter, Dr Reddy’s Gets 483
The US regulator has slammed India’s Emcure Pharmaceuticals in a warning letter, accusing the company of slipshod investigation of tests showing microbial contamination and poor supervision, and has also sent a Form 483 containing eight observations to Dr Reddy’s.
Heritage Is First To Settle DOJ Generic Drug Price Fixing Probe
Heritage agrees to pay $7.1m to resolve civil allegations and a $225,000 criminal penalty. DOJ defers prosecution of one felony charge.
Heritage Is First To Settle DOJ Generic Drug Price Fixing Probe; Will Others Follow?
Heritage agrees to pay $7.1m to resolve civil allegations and a $225,000 criminal penalty. DOJ defers prosecution of one felony charge.